Literature DB >> 9882513

Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells.

M Wang1, Y Xie, L Girnita, G Nilsson, A Dricu, J Wejde, O Larsson.   

Abstract

The Ewing's sarcoma cell line RD-ES, which carries the EWS/FLI-1 fusion gene, responded to the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor lovastatin with growth arrest. Replenishment of mevalonate (MVA) to the arrested cells restored cell growth. However, if tunicamycin (TM), which is an inhibitor of N-linked glycosylation, was present together with MVA the cells remained arrested, indicating that N-linked glycosylation is of importance for growth of Ewing's sarcoma cells. Inhibition of the biosynthesis of EWS/FLI-1 fusion protein by treatment with antisense oligonucleotides also led to growth arrest, suggesting that this protein is of importance for cell growth. We investigated whether MVA synthesis and N-linked glycosylation could be involved in regulation of the expression of the EWS/FLI-1 fusion protein, which in fact contains four potential sites for N-linked glycosylation. We found that inhibition of both HMG-CoA reductase and N-linked glycosylation drastically decreased the expression of the fusion protein, which mainly appears in the cell nuclei. There was no significant difference in the inhibitory effect on the fusion protein between the cytoplasm and the cell nuclei, indicating that the transport of the fusion protein to the cell nucleus is not affected. The fusion protein did not exhibit any gel electrophoretic mobility shift after treatment of the cells with lovastatin or TM, and it did not incorporate [3H]glucosamine. Therefore we can conclude that the fusion protein is not a glycoprotein. The decreased expression of the fusion protein following lovastatin or TM treatment was found to be due to a lowered stability of de novo-synthesized fusion protein. The down-regulation of the fusion protein was correlated to growth arrest. Furthermore, the kinetics between the expression of EWS/FLI-1 fusion protein and the initiation of DNA synthesis in MVA-stimulated cells were similar. Taken together, our data suggest that the regulatory role of N-linked glycosylation in the expression of the EWS/FLI-1 fusion protein is important for growth of Ewing's sarcoma cells. Possible mechanisms underlying TM-induced decrease in EWS/FLI-1 expression may involve the breaking of growth factor receptor pathways. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882513     DOI: 10.1006/excr.1998.4280

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  10 in total

1.  Apposite insulin-like growth factor (IGF) receptor glycosylation is critical to the maintenance of vascular smooth muscle phenotype in the presence of factors promoting osteogenic differentiation and mineralization.

Authors:  Kirk W Siddals; Justine Allen; Smeeta Sinha; Ann E Canfield; Philip A Kalra; J Martin Gibson
Journal:  J Biol Chem       Date:  2011-03-16       Impact factor: 5.157

Review 2.  Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities.

Authors:  S A Burchill
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

3.  O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma.

Authors:  R Bachmaier; D N T Aryee; G Jug; M Kauer; M Kreppel; K A Lee; H Kovar
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

4.  β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.

Authors:  Huiyuan Zheng; Hongchang Shen; Iulian Oprea; Claire Worrall; Radu Stefanescu; Ada Girnita; Leonard Girnita
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-27       Impact factor: 11.205

5.  Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.

Authors:  David Herrero-Martin; Argyro Fourtouna; Stephan Niedan; Lucia T Riedmann; Raphaela Schwentner; Dave N T Aryee
Journal:  Sarcoma       Date:  2011-11-10

Review 6.  Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.

Authors:  Hildur Helgadottir; Iara Rocha Trocoli Drakensjö; Ada Girnita
Journal:  Front Oncol       Date:  2018-06-12       Impact factor: 6.244

7.  Molecular approaches to sarcoma therapy.

Authors:  R J Olsen; S R Tarantolo; S H Hinrichs
Journal:  Sarcoma       Date:  2002

Review 8.  Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation.

Authors:  Leonard Girnita; Claire Worrall; Shin-Ichiro Takahashi; Stefan Seregard; Ada Girnita
Journal:  Cell Mol Life Sci       Date:  2013-11-26       Impact factor: 9.261

Review 9.  Receptor tyrosine kinase targeting in glioblastoma: performance, limitations and future approaches.

Authors:  Oana Alexandru; Cristina Horescu; Ani-Simona Sevastre; Catalina Elena Cioc; Carina Baloi; Alexandru Oprita; Anica Dricu
Journal:  Contemp Oncol (Pozn)       Date:  2020-03-30

10.  Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines.

Authors:  Oana Alexandru; Ani-Simona Sevastre; Juan Castro; Stefan-Alexandru Artene; Daniela Elise Tache; Oana Stefana Purcaru; Veronica Sfredel; Ligia Gabriela Tataranu; Anica Dricu
Journal:  Int J Mol Sci       Date:  2019-09-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.